PT3200791T - Processos e intermediários na preparação de antagonistas c5ar - Google Patents
Processos e intermediários na preparação de antagonistas c5arInfo
- Publication number
- PT3200791T PT3200791T PT158456103T PT15845610T PT3200791T PT 3200791 T PT3200791 T PT 3200791T PT 158456103 T PT158456103 T PT 158456103T PT 15845610 T PT15845610 T PT 15845610T PT 3200791 T PT3200791 T PT 3200791T
- Authority
- PT
- Portugal
- Prior art keywords
- intermediates
- processes
- preparation
- c5ar antagonists
- c5ar
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 239000000543 intermediate Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462057107P | 2014-09-29 | 2014-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3200791T true PT3200791T (pt) | 2020-05-06 |
Family
ID=55583729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT158456103T PT3200791T (pt) | 2014-09-29 | 2015-09-28 | Processos e intermediários na preparação de antagonistas c5ar |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US9745268B2 (pt) |
| EP (2) | EP3200791B1 (pt) |
| JP (1) | JP6898229B6 (pt) |
| KR (2) | KR102593431B1 (pt) |
| CN (2) | CN113121415A (pt) |
| AU (2) | AU2015324111B2 (pt) |
| BR (1) | BR112017006232B1 (pt) |
| CA (2) | CA2960733C (pt) |
| DK (1) | DK3200791T3 (pt) |
| ES (2) | ES2802428T3 (pt) |
| IL (1) | IL251061B (pt) |
| MA (1) | MA52308A (pt) |
| MX (2) | MX368492B (pt) |
| NZ (2) | NZ767823A (pt) |
| PL (1) | PL3200791T3 (pt) |
| PT (1) | PT3200791T (pt) |
| RU (1) | RU2712233C2 (pt) |
| SG (1) | SG11201702185UA (pt) |
| WO (1) | WO2016053890A1 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3078658B1 (en) | 2008-12-22 | 2019-04-10 | ChemoCentryx, Inc. | C5ar antagonists |
| DK2585064T3 (en) * | 2010-06-24 | 2017-07-24 | Chemocentryx Inc | C5aR antagonists |
| WO2016053890A1 (en) | 2014-09-29 | 2016-04-07 | Chemocentryx, Inc. | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS |
| RU2742888C2 (ru) | 2016-01-14 | 2021-02-11 | Кемосентрикс, Инк. | Способ лечения с3-гломерулопатии |
| AU2018359214A1 (en) * | 2017-10-30 | 2020-04-16 | Chemocentryx, Inc. | Deuterated compounds as immunomodulators |
| MX2020013166A (es) | 2018-06-07 | 2021-03-29 | Chemocentryx Inc | Dosificación y efecto del antagonista de c5a con la vasculitis asociada con anca. |
| IL283450B1 (en) | 2018-11-30 | 2024-02-01 | Chemocentryx Inc | Solid solution capsule formulations containing (3S,2R)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl) Piperidine-3-carboxamide, methods for their preparation and their medical uses |
| KR102207333B1 (ko) * | 2019-09-09 | 2021-01-27 | 성균관대학교산학협력단 | 4중 연속 고리 화합물의 신규한 제조방법 |
| KR20220098179A (ko) | 2019-11-08 | 2022-07-11 | 케모센트릭스, 인크. | 보체 성분 C5a 수용체의 유리 염기 결정질 형태 |
| JP2023501789A (ja) | 2019-11-08 | 2023-01-19 | ケモセントリックス，インコーポレイティド | 補体成分Ｃ５ａ受容体の非晶質形態 |
| AU2020380367A1 (en) * | 2019-11-08 | 2022-05-12 | Chemocentryx, Inc. | Salt forms of a complement component C5a receptor |
| WO2022078269A1 (zh) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
| EP4137133A1 (en) | 2021-08-19 | 2023-02-22 | Sandoz AG | Crystalline form of avacopan |
| WO2022263263A1 (en) | 2021-06-16 | 2022-12-22 | Sandoz Ag | Crystalline form of avacopan |
| CN113957106B (zh) * | 2021-11-03 | 2024-04-19 | 暨明医药科技（苏州）有限公司 | 一种Avacopan及其中间体的制备方法 |
| CN114262291B (zh) * | 2022-01-04 | 2023-05-19 | 重庆医科大学 | 一种阿伐可泮的合成方法 |
| WO2023158722A2 (en) | 2022-02-16 | 2023-08-24 | Teva Pharmaceuticals International Gmbh | Processes for preparation of avacopan and intermediates thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4686100A (en) | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
| MXPA01002173A (es) | 1998-08-28 | 2003-07-14 | Scios Inc | Inhibidores de p38-alfa cinasa. |
| RU2197288C2 (ru) | 1999-08-03 | 2003-01-27 | Тверская медицинская академия | Способ лечения больных хроническим гломерулонефритом |
| AU2001259511A1 (en) | 2000-05-05 | 2001-11-20 | Smith Kline Beecham Corporation | Novel anti-infectives |
| WO2002014265A1 (fr) | 2000-08-10 | 2002-02-21 | Mitsubishi Pharma Corporation | Nouveaux derives d'uree substitues en position 3, et leur utilisation en medecine |
| PT1318140E (pt) | 2000-09-14 | 2011-05-26 | Mitsubishi Tanabe Pharma Corp | Novos derivados de amida e sua utiliza??o medicinal |
| BR0017338A (pt) | 2000-09-29 | 2004-04-27 | Neurogen Corp | Composto, processo para preparar um composto, composição farmacêutica, e métodos para tratar um paciente, para inibir quimiotaxia celular promovida com c5a, para localizar receptores de c5a em um tecido, e para reduzir a gravidade ou frequência de uma ou mais sequelas inflamatórias de transplante de órgão |
| SE524438C2 (sv) | 2000-10-05 | 2004-08-10 | Magnus Georg Goertz | Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium |
| DE10293171D2 (de) | 2001-07-19 | 2004-07-01 | Luk Lamellen & Kupplungsbau | Ausrücksystem zur Betätigung einer Kupplung eines Fahrzeuges |
| BRPI0211953B8 (pt) | 2001-08-17 | 2021-05-25 | Genentech Inc | anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro |
| IL160700A0 (en) | 2001-09-21 | 2004-08-31 | Mitsubishi Pharma Corp | 3-substituted-4-pyrimidone derivatives |
| ITMI20012025A1 (it) | 2001-09-28 | 2003-03-28 | Dompe Spa | Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono |
| US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| WO2003082826A1 (en) | 2002-03-28 | 2003-10-09 | Neurogen Corporation | Substituted biaryl amides as c5a receptor modulators |
| EP1487798A4 (en) | 2002-03-28 | 2005-07-13 | Neurogen Corp | Substituted tetrahydroisoquinolines as C5A receptor modulators |
| JP2005530719A (ja) | 2002-03-29 | 2005-10-13 | ニューロジェン コーポレーション | 病原性炎症要素を有する状態の治療のための組み合わせ療法 |
| US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| WO2004014905A1 (en) | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzimidazole compounds |
| US7169775B2 (en) | 2002-08-21 | 2007-01-30 | Neurogen Corporation | Amino methyl imidazoles as C5a receptor modulators |
| FR2846654A1 (fr) | 2002-11-05 | 2004-05-07 | Servier Lab | Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2004043223A2 (en) | 2002-11-05 | 2004-05-27 | The Regents Of The University Of Michigan | Compositions and methods for the diagnosis and treatment of sepsis |
| ATE552253T1 (de) | 2002-11-08 | 2012-04-15 | Novartis Int Pharm Ltd | 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren |
| AU2003902354A0 (en) | 2003-05-15 | 2003-05-29 | Harkin, Denis W. | Treatment of haemorrhagic shock |
| BRPI0410630A (pt) | 2003-06-19 | 2006-06-13 | Pfizer Prod Inc | antagonista de nk1 |
| WO2005007087A2 (en) | 2003-07-03 | 2005-01-27 | Neurogen Corporation | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| EA200700117A1 (ru) | 2004-06-24 | 2007-06-29 | Инсайт Корпорейшн | N-замещенные пиперидины и их применение в качестве фармацевтических препаратов |
| EP1621536A1 (en) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
| WO2006071958A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| UA94901C2 (ru) | 2005-02-18 | 2011-06-25 | Астразенека Аб | Антибактериальные производные пиперидина |
| WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| WO2007051062A2 (en) | 2005-10-28 | 2007-05-03 | Chemocentryx, Inc. | Substituted dihydropyridines and methods of use |
| LT1951663T (lt) | 2005-11-24 | 2016-11-10 | Dompé Farmaceutici S.P.A. | (r)-arilalkilamino dariniai ir juos turinčios farmacinės kompozicijos |
| KR20140057635A (ko) | 2006-03-15 | 2014-05-13 | 알렉시온 파마슈티칼스, 인코포레이티드 | 보체의 저해물질로 발작성 야간혈색뇨증 환자의 치료 |
| WO2008022060A2 (en) | 2006-08-14 | 2008-02-21 | Novartis Ag | Imidazo-pyridine derivatives for modulating protein kinase activity |
| EP2077842A2 (en) | 2006-10-31 | 2009-07-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of an egfr antagonist for the treatment of glomerolonephritis |
| WO2009004650A1 (en) | 2007-06-29 | 2009-01-08 | Torrent Pharmaceuticals Ltd. | Novel substituted piperidones as hsp inducers |
| CN102177152A (zh) | 2008-08-11 | 2011-09-07 | 哈佛大学校长及研究员协会 | 用于抑制tRNA合成酶的卤夫酮(halofuginone)类似物和其用途 |
| AU2009290137A1 (en) | 2008-09-03 | 2010-03-11 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
| US20100074863A1 (en) | 2008-09-17 | 2010-03-25 | Yat Sun Or | Anti-infective pyrrolidine derivatives and analogs |
| NZ614351A (en) | 2008-11-10 | 2015-05-29 | Alexion Pharma Inc | Methods and compositions for treating complement-associated disorders |
| EP3078658B1 (en) * | 2008-12-22 | 2019-04-10 | ChemoCentryx, Inc. | C5ar antagonists |
| US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| WO2011035143A2 (en) | 2009-09-17 | 2011-03-24 | The Regents Of The University Of Michigan | Methods and compositions for inhibiting rho-mediated diseases and conditions |
| DK2585064T3 (en) | 2010-06-24 | 2017-07-24 | Chemocentryx Inc | C5aR antagonists |
| BR112014031375A2 (pt) | 2012-06-20 | 2017-06-27 | Novartis Ag | moduladores da série de reação complementar e usos dos mesmos |
| CN105392803B (zh) | 2013-05-08 | 2019-12-06 | 诺和诺德股份有限公司 | C5aR拮抗剂的用途 |
| WO2016053890A1 (en) * | 2014-09-29 | 2016-04-07 | Chemocentryx, Inc. | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS |
| RU2742888C2 (ru) | 2016-01-14 | 2021-02-11 | Кемосентрикс, Инк. | Способ лечения с3-гломерулопатии |
| MA44629A (fr) | 2016-04-04 | 2021-03-24 | Chemocentryx Inc | Antagonistes de c5ar solubles |
| MX2023007420A (es) | 2020-12-21 | 2023-06-29 | Chemocentryx Inc | Tratamiento de glomerulopatia c3 usando un inhibidor de c5a. |
-
2015
- 2015-09-28 WO PCT/US2015/052697 patent/WO2016053890A1/en active Application Filing
- 2015-09-28 RU RU2017114960A patent/RU2712233C2/ru active
- 2015-09-28 AU AU2015324111A patent/AU2015324111B2/en active Active
- 2015-09-28 MX MX2017003789A patent/MX368492B/es active IP Right Grant
- 2015-09-28 CA CA2960733A patent/CA2960733C/en active Active
- 2015-09-28 DK DK15845610.3T patent/DK3200791T3/da active
- 2015-09-28 NZ NZ767823A patent/NZ767823A/en unknown
- 2015-09-28 SG SG11201702185UA patent/SG11201702185UA/en unknown
- 2015-09-28 ES ES15845610T patent/ES2802428T3/es active Active
- 2015-09-28 PL PL15845610T patent/PL3200791T3/pl unknown
- 2015-09-28 KR KR1020177011789A patent/KR102593431B1/ko active IP Right Grant
- 2015-09-28 MA MA052308A patent/MA52308A/fr unknown
- 2015-09-28 EP EP15845610.3A patent/EP3200791B1/en active Active
- 2015-09-28 US US14/867,669 patent/US9745268B2/en active Active
- 2015-09-28 ES ES20160995T patent/ES2926828T3/es active Active
- 2015-09-28 JP JP2017516679A patent/JP6898229B6/ja active Active
- 2015-09-28 CA CA3220371A patent/CA3220371A1/en active Pending
- 2015-09-28 CN CN202110432100.1A patent/CN113121415A/zh active Pending
- 2015-09-28 NZ NZ730123A patent/NZ730123A/en unknown
- 2015-09-28 BR BR112017006232-1A patent/BR112017006232B1/pt active IP Right Grant
- 2015-09-28 PT PT158456103T patent/PT3200791T/pt unknown
- 2015-09-28 KR KR1020237035689A patent/KR20230149873A/ko active Application Filing
- 2015-09-28 EP EP20160995.5A patent/EP3682879B1/en active Active
- 2015-09-28 CN CN201580052937.6A patent/CN106999481B/zh active Active
-
2017
- 2017-03-09 IL IL251061A patent/IL251061B/en active IP Right Grant
- 2017-03-23 MX MX2019011911A patent/MX2019011911A/es unknown
- 2017-07-25 US US15/659,468 patent/US10266492B2/en active Active
-
2019
- 2019-03-21 US US16/360,195 patent/US10532982B2/en active Active
- 2019-12-06 US US16/706,296 patent/US20200354320A1/en not_active Abandoned
-
2021
- 2021-06-22 AU AU2021204209A patent/AU2021204209B2/en active Active
-
2022
- 2022-02-08 US US17/667,289 patent/US11845729B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251061B (en) | Processes and building materials in the preparation of c5ar antagonists | |
| IL279606A (en) | Anti-TREM2 antibodies and methods of using them | |
| HK1243102A1 (zh) | 抗cd79b抗體和使用方法 | |
| IL250415B (en) | Antibodies against pd-l and methods of using them | |
| HRP20181359T1 (hr) | Anti-jagged1 protutijela i postupci uporabe | |
| IL251868B (en) | Anti-tim3 antibodies and methods of use | |
| GB201421847D0 (en) | Dispensers and methods of use thereof | |
| IL251165A0 (en) | Anti-il-1beta antibodies and methods of their use | |
| IL247754A0 (en) | Antibodies against mcam and related methods of use | |
| IL247315A0 (en) | Anti-acth antibodies and their uses | |
| HK1250146A1 (zh) | 抗前-bcr拮抗劑和方法 | |
| IL251286A0 (en) | Anti-pdgf-b antibodies and methods of use | |
| ZA201604870B (en) | Recombinant microorganisms and methods of use thereof | |
| HK1246288A1 (zh) | S1pr2拮抗劑及其用途 | |
| IL247448A0 (en) | Peptides and methods of use | |
| GB201509977D0 (en) | Dispensers and methods of use thereof | |
| PL3229772T3 (pl) | 6-arylo-9-glikozylopuryny i ich zastosowanie | |
| GB201404133D0 (en) | Garment and method of use thereof |